BNTX

BioNTech SE (BNTX) is the lead sponsor of 32 active clinical trials listed on ClinicalTrials.gov^[4], including 9 Phase 3^[1], 20 Phase 2^[2], 15 Phase 1^[3].

Trial NCT06712316^[5] evaluates Pumitamig in Non-small Cell Lung Cancer with a target enrollment of 1260 participants. Trial NCT04534205^[6] evaluates BNT113 in Unresectable Head and Neck Squamous Cell Carcinoma with a target enrollment of 350 participants. Trial NCT07300839^[7] evaluates BNT162b2 Vaccine in COVID-19 with a target enrollment of 25500 participants.

No Form 4 insider filings for BNTX were recorded at the SEC in the past 30 days^[8].